Tatton-Brown-Rahman syndrome with a novel DNMT3A mutation presented severe intellectual disability and autism spectrum disorder

Takayuki Yokoi1,2, Yumi Enomoto3, Takuya Naruto4, Kenji Kurosawa5 and Norimichi Higurashi1

Abstract

Tatton-Brown-Rahman syndrome is a congenital anomaly syndrome that manifests with overgrowth, macrocephaly, and characteristic facial features. This autosomal dominant disease is caused by a germline mutation in DNMT3A. Some patients with this syndrome develop mild to severe intellectual disability, which is sometimes accompanied by autism spectrum disorder or other developmental disorders. We report a Japanese patient with severe intellectual disability and autism spectrum disorder with a de novo mutation in the active domain of DNMT3A.

There are several congenital anomaly syndromes that exhibit overgrowth. Tatton-Brown-Rahman syndrome (TBRS) was clinically reported together with the responsible gene DNMT3A in 2014 and is a relatively new overgrowth congenital anomaly syndrome1. DNMT3A: DNA methyltransferase 3 alpha is involved in DNA de novo methylation essential for genome regulation and development. In addition to overgrowth, patients with TBRS also have macrocephaly, dysmorphic facial features and intellectual disability (ID) with or without autism spectrum disorder (ASD). TBRS is inherited in an autosomal dominant manner; most of the mutations are de novo mutations1–6. To date, there are approximately 80 reported cases1–8. Various mutations have been found at various sites in previous reports of TBRS. Originally, somatic mutations of DNMT3A were identified in acute myeloid leukemia. There have been several reports of TBRS with the same mutation as acute myeloid leukemia1–6. ID varies from mild to severe, and it can be combined with developmental disorders. Here, we report a case of TBRS with a novel mutation and severe ID and ASD.

The proband was a 3-year-old Japanese boy born to nonconsanguineous healthy parents. He was born at 37 weeks of gestation with a birth weight of 3630 g (+3.2 S.D.), a length of 98.1 cm (+1.8 S.D.), and head circumference of 35.5 cm (+2.1 S.D.). His weight was 23.5 kg (+2.3 S.D.), his height was 117 cm (+2.4 S.D.), and his head circumference was 54.5 cm (+4.2 S.D.) at 5 years of age. Although his motor developmental milestone was within normal limits, his intellectual developmental milestone was delayed. He began to speak a single word at 2 years and 8 months of age and could speak several words at 3 years. He could follow only very easy and simple instructions. He developed complex febrile seizures at the age of 2 years. Physical examination revealed dysmorphic features, including narrow forehead, synophrys, hypertelorism, depressed nasal bridge, and an upturned nose (Fig. 1a). His brain MRI showed no abnormal findings. Because hyperactivity and autistic behavior were remarkable, it was difficult to carry out any developmental testing. His karyotype analysis was 46,XY, and deletion of 5q35 was not detected by fluorescence in situ hybridization (FISH) analysis.

Written informed consent was obtained from the parents of the patients in accordance with the Kanagawa
Total genomic DNA was obtained from lymphocytes using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) following the manufacturer’s instructions. DNA libraries were enriched for sequences using TruSight One (Illumina Inc., San Diego, CA, USA), which enables enrichment and final analysis of a panel of 4,813 genes. Patient samples were sequenced by MiSeq (Illumina Inc.) with 150-bp paired-end reads. Data were analyzed using the Burrows–Wheeler alignment tool and the Genome Analysis Toolkit pipeline (Broad Institute, Cambridge, MA, USA) and visualized in the Integrative Genomics Viewer (IGV). Calling copy-number variation (CNV) was based on log–ratio analysis and read depth z-score of each exon. Mutations identified by targeted sequencing were confirmed by Sanger sequencing, and appropriate segregation was demonstrated by phenotype in the unaffected parents.

Targeted sequencing identified a novel mutation, c.1904G>A: p.R635Q (NM_175629), in DNMT3A (Fig. 1b). The mutation was absent in a human genetic variation database (the Japanese genetic variation consortium: a reference database of genetic variations in the Japanese population comprising 1208 individuals [http://www.genome.med.kyoto-u.ac.jp/SnpDB]), the 1000 Genomes project, the National Heart, Lung, and Blood Institute (NHLBI) grant opportunity exome sequencing project (ESP), the Exome Aggregation Consortium (ExAC), and our 600 in-house control Japanese genomic samples. In silico analysis according to ANNOVAR, with predictions for c.1904G>A (p.R635Q), indicated a deleterious effect by SIFT (http://sift.jcvi.org/), Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/), and MutationTaster (http://mutect.tumor.de/MutationTaster/). Sanger sequencing demonstrated that the mutation was de novo.

Although it was a missense mutation, the phenotype could be more distinctive and severe due to the mutation of the active domain. In this case, the ID was severe. We could not derive the relationship between the severity of mental retardation and the position/type of mutation either from this study or in comparison to previous reports (Fig. 2a, b)1–6. Our patient displayed autistic behavior. Similarly, the relationship between the presence or absence of autism and the position and type of mutation is unknown. Additionally, the relationship between ID and ASD is unknown (data not shown).

In some congenital anomalies that exhibit overgrowth, such as TBRS, tumorigenesis may be seen. Another mutation in DNMT3A, p.R882H, in its active domain, has been identified as somatic mutations in leukemic cells. One patient with this mutation developed acute myeloid leukemia4. In our patient, the mutation was in the active domain. However, no onset of leukemia or other blood abnormalities was observed in our patient. Although it is unknown whether this mutation leads to leukemia, it is important to screen for the onset of leukemia in the future.

In conclusion, we presented a patient with TBRS with a novel mutation. He had severe ID and ASD. Since the severity of ID, ASD, and leukemia is significantly related to the prognosis and quality of life, if the genotype-phenotype correlation is known, it is very useful for patients and their families. It is necessary to accumulate future cases.
The relevant data from this Data Report are hosted at the Human Genome Variation Database at https://doi.org/10.6084/m9.figshare.hgv.2844.

Acknowledgements
This research was supported in part by a Grant-in-Aid from the Ministry of Health, Labour, and Welfare, Japan; the Intramural Research Grant (grant number, 24–8) for Neurological and Psychiatric Disorders of National Center of Neurology and Psychiatry (NCNP); and CREST, Japan Science and Technology Agency (to K.K.). We thank the patients and their families for their cooperation.

Author details
1Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan. 2Division of Medical Genetics, Kanagawa Children’s Medical Center, Yokohama, Japan. 3Clinical Research Institute, Kanagawa Children’s Medical Center, Yokohama, Japan. 4Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 12 September 2019 Revised: 2 December 2019 Accepted: 15 April 2020

Published online: 18 May 2020

References
1. Tatton-Brown, K. et al. Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability. Nat. Genet. 46, 385–388 (2014).
2. Tlemsani, C. et al. SETD2 and DNMT3A screen in the Sotos-like syndrome French cohort. J. Med Genet. 53, 743–751 (2016).
3. Kosaki, R., Terashima, H., Kubota, M. & Kosaki, K. Acute myeloid leukemia-associated DNMT3A p.Arg882His mutation in a patient with Tatton-Brown-Rahman overgrowth syndrome as a constitutional mutation. Am. J. Med. Genet. A 173, 250–253 (2017).
4. Hollink, I. H. I. M. et al. Acute myeloid leukaemia in a case with Tatton-Brown-Rahman syndrome: the peculiar DNMT3A R882 mutation. J. Med. Genet. 54, 805–808 (2017).
5. Tatton-Brown, K. et al. The Tatton-Brown-Rahman Syndrome: a clinical study of 55 individuals with de novo constitutive DNMT3A variants. Wellcome Open Res. 3, 46 (2018).
6. Shen, W. et al. The spectrum of DNMT3A variants in Tatton-Brown-Rahman syndrome overlaps with that in hematologic malignancies. Am. J. Med. Genet. A 173, 3022–3028 (2017).
7. Xin, B. et al. Novel DNMT3A germline mutations are associated with inherited Tatton-Brown-Rahman syndrome. Clin. Genet. 91, 623–628 (2017).
8. Lemire, G. et al. A case of familial transmission of the newly described DNMT3A-Overgrowth Syndrome. Am. J. Med. Genet. A 173, 1887–1890 (2017).